Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary
kidney disease and one of the most common causes of end-stage kidney disease. Multiple …

Diabetic kidney disease remains the most common cause of end-stage kidney disease in
the world. Despite reductions in incidence rates of myocardial infarction and stroke in people …

Approval of the vasopressin V2 receptor antagonist tolvaptan—based on the landmark
TEMPO 3: 4 trial—marked a transformation in the management of autosomal dominant …

Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited
cause of kidney failure, accounting for 5%-10% of cases. Predicting which patients with …

In the TEMPO 3: 4 Trial, treatment with tolvaptan, a vasopressin V2 receptor antagonist,
slowed the increase in total kidney volume and decline in estimated glomerular filtration rate …

The natural history of autosomal dominant polycystic kidney disease (ADPKD) is
characterized by a variable rate of cyst development and increase in total kidney volume …

The kidneys, by equilibrating the outputs to the inputs, are essential for maintaining the
constant volume, pH, and electrolyte composition of the internal milieu. Inability to do so …

Background Autosomal dominant polycystic kidney disease (ADPKD) is the most frequent
genetically determined renal disease. In affected patients, renal function may progressively …

Treatment with sodium-glucose cotransporter-2 (SGLT2) inhibitors may have pleiotropic and
beneficial effects in terms of ameliorating of risk factors for the progression of autosomal …

Rationale & Objective The vasopressin V2 receptor antagonist (V2RA) tolvaptan is the first
drug that has been shown to slow the rate of kidney function decline in patients with …